Novartis India Ltd

Novartis India Annual General Meeting

Novartis India issued a corrigendum to its 78th AGM notice. This correction clarifies ESOP 2026 scheme details and the company's nature of industry.

Novartis India Earnings Call Transcript: Key Takeaways

Novartis India transition to ChrysCapital ownership (70.68%), pivoting from a partner-led model to a direct, in-house commercial platform focusing on chronic therapies like cardiology and ophthalmology.

Novartis India Investor Presentation: Key Takeaways

Novartis India Limited (NIL) shifts to a direct-to-market model under new ownership by ChrysCapital, acquiring the 'Minipress' brand for ₹1,250 Cr and in-licensing an ophthalmic portfolio.

Novartis India Other Announcement

Novartis India dispatched physical letters with the FY25-26 Annual Report web-link to non-email shareholders per Reg 36(1)(b). This is a routine compliance communication with no financial or business impact.

Novartis India Partnership

Novartis India signed an exclusive distribution deal with Novartis Healthcare for its retina portfolio in India. Upfront consideration of INR 10 Crore expands NIL's ophthalmology presence.

Value

₹10.00 Cr

Novartis India Business Update

Novartis India acquired trademarks 'Minipress' and 'Minipres' from Pfizer for ₹1,250.001 Crore. The IP acquisition strengthens its hypertension and BPH portfolio in India.

Value

₹1,250 Cr

Novartis India Acquisition Worth ₹1,250 Cr

Novartis India acquired Minipress/Minipres trademarks and related IP from Pfizer for ₹1,250 Crore. The board approved and the asset purchase agreement was executed on September 7, 2026.

Value

₹1,250 Cr

Novartis India Annual General Meeting

Novartis India Limited submits its Annual Report for FY 2025-26 and notice for the 78th Annual General Meeting scheduled on September 24, 2026.